CeriBell, Inc. CBLL
26.01 USD -1.38 (-5.04%)
At closeNov 5, 2026, 4:39 PM EST
26.01 0.00 0.00%
After hours · Nov 5, 4:39 PM ET
25.81 Day range 28.00
11.56 52-week range 28.27
- YTD
- +18.60%
- 1 year
- +120.80%
News
benzinga.com Canaccord Genuity Maintains Buy on CeriBell, Raises Price Target to $33 Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and raises the price target from $26 to $33.
zacks.com CeriBell, Inc. (CBLL) Reports Q3 Loss, Tops Revenue Estimates CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.37 per share a year ago.
seekingalpha.com CeriBell, Inc. (CBLL) Q3 2026 Earnings Call Transcript CeriBell, Inc. (CBLL) Q3 2026 Earnings Call Transcript
zacks.com Compared to Estimates, CeriBell, Inc. (CBLL) Q3 Earnings: A Look at Key Metrics The headline numbers for CeriBell, Inc. (CBLL) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall…
marketbeat.com CeriBell Q3 Earnings Call Highlights CeriBell NASDAQ: CBLL reported third-quarter revenue growth of approximately 30% as the company added a record number of hospital accounts and increased usage of its seizure-monitoring platform among…
benzinga.com CeriBell Q3 2026 Earnings Call Transcript CeriBell (NASDAQ:CBLL) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com CeriBell Raises FY2026 Sales Guidance from $114.000M-$117.000M to $115.000M-$117.000M vs $115.537M Est CeriBell (NASDAQ:CBLL) raises FY2026 sales outlook from $114.000 million-$117.000 million to $115.000 million-$117.000 million vs $115.537 million estimate.
benzinga.com CeriBell Q3 EPS $(0.55) Misses $(0.51) Estimate, Sales $29.341M Beat $29.164M Estimate CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.51) by 7.84 percent. This is a 48.65 percent decrease over losses of $(0.37)…
globenewswire.com Ceribell Reports Third Quarter 2026 Financial Results SUNNYVALE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with…
globenewswire.com Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution SUNNYVALE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of…
globenewswire.com Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum SUNNYVALE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with…
globenewswire.com Ceribell to Report Third Quarter 2026 Financial Results on November 3, 2026 SUNNYVALE, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with…
benzinga.com TD Cowen Maintains Buy on CeriBell, Raises Price Target to $33 TD Cowen analyst Joshua Jennings maintains CeriBell (NASDAQ:CBLL) with a Buy and raises the price target from $29 to $33.
globenewswire.com Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis SUNNYVALE, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of…
defenseworld.net BlackRock Inc. Acquires New Holdings in CeriBell, Inc. $CBLL BlackRock Inc. bought a new position in shares of CeriBell, Inc. (NASDAQ: CBLL) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The…
defenseworld.net Bank of America Corp DE Has $5.86 Million Position in CeriBell, Inc. $CBLL Bank of America Corp DE boosted its holdings in CeriBell, Inc. (NASDAQ: CBLL) by 15.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and…
benzinga.com Snowflake To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC…- benzinga.com BTIG Maintains Buy on CeriBell, Raises Price Target to $30 BTIG analyst Marie Thibault maintains CeriBell (NASDAQ:CBLL) with a Buy and raises the price target from $28 to $30.
marketbeat.com CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push CeriBell NASDAQ: CBLL outlined its plans to expand its brainwave-monitoring platform beyond seizure detection, pointing to new products for delirium, pediatric patients and eventually stroke as it…- benzinga.com Canaccord Genuity Maintains Buy on CeriBell, Raises Price Target to $26 Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and raises the price target from $25 to $26.
seekingalpha.com CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript
zacks.com Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings Although the revenue and EPS for CeriBell, Inc. (CBLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall…
zacks.com CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.38 per share a year ago.
marketbeat.com CeriBell Q2 Earnings Call Highlights CeriBell NASDAQ: CBLL reported second-quarter 2026 revenue growth of 33% as increased utilization at existing hospital accounts and continued customer additions supported results. The company also…
benzinga.com CeriBell Raises FY2026 Sales Guidance from $112.000M-$116.000M to $114.000M-$117.000M vs $113.979M Est CeriBell (NASDAQ:CBLL) raises FY2026 sales outlook from $112.000 million-$116.000 million to $114.000 million-$117.000 million vs $113.979 million estimate.- benzinga.com CeriBell Announces FDA 510(k) Clearance For Two New AI Algorithm Enhancements Integrated Directly Into Existing Cloud-Based Neurology Portal: Epileptiform Abnormality Detection And Artifact Reduction CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today
globenewswire.com Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review SUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of…- benzinga.com CeriBell Says U.S. CMS Grants New Technology Add-On Payment For Up To $2,171 Per Eligible Medicare Patient Case Utilizing Ceribell Delirium Monitor System CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today
globenewswire.com Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System Incremental NTAP Reimbursement Stands to Broaden Access to First-of-Its-Kind Dual Seizure and Delirium Monitoring Platform Incremental NTAP Reimbursement Stands to Broaden Access to First-of-Its-Kind…
globenewswire.com Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O'Keefe SUNNYVALE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with…
globenewswire.com Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference SUNNYVALE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with…- benzinga.com CeriBell Highlights Publication Of New Research Paper, 'Point-Of-Care EEG Artificial Intelligence Measure Of Seizure Burden Associates With Clinical Outcome At Discharge' CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that a…
- benzinga.com Canaccord Genuity Maintains Buy on CeriBell, Lowers Price Target to $25 Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and lowers the price target from $28 to $25.
- benzinga.com CeriBell Raises FY2026 Sales Guidance from $111.000M-$115.000M to $112.000M-$116.000M vs $113.138M Est CeriBell (NASDAQ:CBLL) raises FY2026 sales outlook from $111.000 million-$115.000 million to $112.000 million-$116.000 million vs $113.138 million estimate.
benzinga.com CeriBell Q1 EPS $(0.52) Misses $(0.39) Estimate, Sales $26.494M Beat $26.088M Estimate CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.39) by 33.33 percent. This is a 44.44 percent decrease over losses of $(0.36)…
benzinga.com Earnings Scheduled For May 11, 2026 - benzinga.com CeriBell Q4 EPS $(0.36) Beats $(0.41) Estimate, Sales $24.784M Beat $23.942M Estimate CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.41) by 12.62 percent. This is a 10 percent increase over losses of $(0.40) per…
- benzinga.com Earnings Scheduled For February 24, 2026
benzinga.com CeriBell's Earnings: A Preview 
benzinga.com Forecasting The Future: 5 Analyst Projections For CeriBell - benzinga.com Canaccord Genuity Maintains Buy on CeriBell, Raises Price Target to $30 Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and raises the price target from $29 to $30.
benzinga.com Academy Sports and Outdoors, Tronox, STAAR Surgical And Other Big Stocks Moving Higher On Tuesday - benzinga.com CeriBell's Clarity Algorithm Gets FDA's Clearance To Detect Electrographic Seizures In Newborns Pre-Term, Older CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that…
benzinga.com JP Morgan Maintains Overweight on CeriBell, Lowers Price Target to $17 JP Morgan analyst Robbie Marcus maintains CeriBell (NASDAQ:CBLL) with a Overweight and lowers the price target from $21 to $17.
benzinga.com TD Cowen Maintains Buy on CeriBell, Lowers Price Target to $20 TD Cowen analyst Joshua Jennings maintains CeriBell (NASDAQ:CBLL) with a Buy and lowers the price target from $36 to $20.- benzinga.com CeriBell Raises FY2025 Sales Guidance from $85.000M-$88.000M to $87.000M-$89.000M vs $86.940M Est 2025 Financial OutlookCeribell is raising its revenue guidance for the full year 2025 to a range of $87 million to $89 million, representing growth of approximately 33% to 36% over the company's…
- benzinga.com CeriBell Q3 EPS $(0.37) Beats $(0.41) Estimate, Sales $22.589M Beat $21.779M Estimate CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.41) by 10.41 percent. This is a 80 percent increase over losses of $(1.85) per…
benzinga.com Earnings Scheduled For November 4, 2025 - benzinga.com Raymond James Initiates Coverage On CeriBell with Strong Buy Rating, Announces Price Target of $19 Raymond James analyst Jayson Bedford initiates coverage on CeriBell (NASDAQ:CBLL) with a Strong Buy rating and announces Price Target of $19.
- benzinga.com CeriBell Q2 EPS $(0.38) Beats $(0.40) Estimate, Sales $21.199M Beat $20.528M Estimate CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.40) by 4.52 percent. The company reported quarterly sales of $21.199 million…